Published in J Antimicrob Chemother on December 04, 2003
Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med (2012) 1.58
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J (2011) 1.34
HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites. J Infect Dis (2009) 1.24
Molecular Basis for Drug Resistance in HIV-1 Protease. Viruses (2010) 1.20
Single-molecule fluorescence spectroscopy using phospholipid bilayer nanodiscs. Methods Enzymol (2010) 1.17
Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor. J Clin Invest (2005) 1.13
Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos (2011) 1.08
Premature and accelerated aging: HIV or HAART? Front Genet (2013) 1.01
Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. J Med Chem (2010) 0.93
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS (2011) 0.91
Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics (2011) 0.91
Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients. Br J Clin Pharmacol (2010) 0.89
Iatrogenic Cushing's syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol (2008) 0.89
The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol (2015) 0.88
Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients. J Virol (2007) 0.85
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chem Biol (2013) 0.84
HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl) (2015) 0.82
Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors. PLoS One (2010) 0.82
Mg supplementation attenuates ritonavir-induced hyperlipidemia, oxidative stress, and cardiac dysfunction in rats. Am J Physiol Regul Integr Comp Physiol (2013) 0.81
Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells. AIDS Res Hum Retroviruses (2010) 0.80
Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden? Patient Prefer Adherence (2011) 0.80
Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochem Pharmacol (2014) 0.80
Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations. Antimicrob Agents Chemother (2014) 0.80
Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2004) 0.79
A structure-activity relationship study on multi-heterocyclic molecules: two linked thiazoles are required for cytotoxic activity. Medchemcomm (2012) 0.79
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. BMC Infect Dis (2013) 0.79
Optimizing treatment for African Americans and Latinos with HIV/AIDS. J Natl Med Assoc (2005) 0.79
Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. Contraception (2014) 0.78
The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir. Drug Metab Dispos (2013) 0.78
Caenorhabditis elegans as a Model System for Studying Drug Induced Mitochondrial Toxicity. PLoS One (2015) 0.77
High prevalence of PI resistance in patients failing second-line ART in Vietnam. J Antimicrob Chemother (2015) 0.77
Human immunodeficiency virus and its effects on the visual system. Infect Dis Rep (2012) 0.77
Recent key advances in human immunodeficiency virus medicine and implications for China. AIDS Res Ther (2010) 0.76
Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments. World J Hepatol (2015) 0.76
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. BMC Infect Dis (2017) 0.75
Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro. Antimicrob Agents Chemother (2017) 0.75
Retinal toxicity with Ritonavir. Int J Ophthalmol (2016) 0.75
Determination of Phenotypic Resistance Cutoffs from Routine Clinical Data. J Acquir Immune Defic Syndr (2016) 0.75
Mg supplementation protects against ritonavir-mediated endothelial oxidative stress and hepatic eNOS downregulation. Free Radic Biol Med (2014) 0.75
The Pharmacokinetic Interaction between Ivacaftor and Ritonavir in Healthy Volunteers. Br J Clin Pharmacol (2017) 0.75
Heterocycle thiazole compounds exhibit antifungal activity through increase in the production of reactive oxygen species in Cryptococcus neoformans/Cryptococcus gattii species complex. Antimicrob Agents Chemother (2017) 0.75
Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab (2005) 5.64
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res (2004) 2.23
Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther (2002) 1.27
Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum (2004) 1.24
Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. J Am Geriatr Soc (2004) 1.06
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. J Clin Rheumatol (2006) 1.03
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin (2003) 0.92
Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. Am J Geriatr Pharmacother (2012) 0.90
Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause (2004) 0.87
A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain. Curr Med Res Opin (2004) 0.85
Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. Curr Med Res Opin (2004) 0.83
A double-blind randomized controlled trial of rofecoxib and multidose oxycodone/acetaminophen in dental impaction pain. J Oral Maxillofac Surg (2007) 0.82
Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. J Rheumatol (2005) 0.82
Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2004) 0.79
A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother (2005) 0.78
The time to onset and overall analgesic efficacy of rofecoxib 50 mg: a meta-analysis of 13 randomized clinical trials. Clin J Pain (2005) 0.78
Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen. J Acquir Immune Defic Syndr (2002) 0.75